MEF-2 isoforms’ (A-D) roles in development and tumorigenesis

Kiran Madugula; Ria Mulherkar; Zafar K. Khan; DeGaulle I. Chigbu; Dip Patel; Edward W. Harhaj; Pooja Jain

doi:10.18632/oncotarget.26763

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

MEF-2 isoforms’ (A-D) roles in development and tumorigenesis

Kiran Madugula, Ria Mulherkar, Zafar K. Khan, DeGaulle I. Chigbu, Dip Patel, Edward W. Harhaj and Pooja Jain _

PDF | Full Text | How to cite

Oncotarget. 2019; 10:2755-2787. https://doi.org/10.18632/oncotarget.26763

Metrics: PDF 2143 views | Full Text 4947 views | ?

Abstract

Kiran Madugula1, Ria Mulherkar1, Zafar K. Khan1, DeGaulle I. Chigbu1, Dip Patel1, Edward W. Harhaj2 and Pooja Jain1

1Department of Microbiology and Immunology, the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19129, USA

2Department of Microbiology and Immunology, Penn State College of Medicine, Hershey, PA 17033, USA

Correspondence to:

Pooja Jain, email: [email protected]

Keywords: MEF-2; HDACs; HDACi; HTLV-1; ATLL

Received: November 26, 2018 Accepted: February 01, 2019 Published: April 12, 2019

ABSTRACT

Myocyte enhancer factor (MEF)-2 plays a critical role in proliferation, differentiation, and development of various cell types in a tissue specific manner. Four isoforms of MEF-2 (A-D) differentially participate in controlling the cell fate during the developmental phases of cardiac, muscle, vascular, immune and skeletal systems. Through their associations with various cellular factors MEF-2 isoforms can trigger alterations in complex protein networks and modulate various stages of cellular differentiation, proliferation, survival and apoptosis. The role of the MEF-2 family of transcription factors in the development has been investigated in various cell types, and the evolving alterations in this family of transcription factors have resulted in a diverse and wide spectrum of disease phenotypes, ranging from cancer to infection. This review provides a comprehensive account on MEF-2 isoforms (A-D) from their respective localization, signaling, role in development and tumorigenesis as well as their association with histone deacetylases (HDACs), which can be exploited for therapeutic intervention.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26763

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

MEF-2 isoforms’ (A-D) roles in development and tumorigenesis

Abstract